TBNHealth
The future of heart drug research in the wake of study setbacks
Publication: STAT
Author: Adam Feuerstein and Elaine Chen
Source published: 13/11/2026, 13:34:45 UTC
Briefing created: 14/11/2026, 11:01:19 UTC
Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 14/11/2026, 10:07:25 UTC.
Briefings
Recent setbacks in heart disease drug development following the American Heart Association meeting in 2025, where two genetically validated drugs showed no clinical benefit, have raised concerns about future cardiovascular research. The evidence highlights that while genetic understanding was once expected to accelerate drug creation, recent trial results have challenged this optimism, prompting questions about the efficacy of current approaches.
Key points
- Two heart disease drugs developed over the past few years failed in clinical trials at the American Heart Association meeting in 2025, showing no benefit despite prior genetic validation.
- The failure of these drugs has prompted industry leaders to reconsider the role of genetic research in accelerating the development of new cardiovascular medicines.
Context
The article discusses the 2025 American Heart Association meeting where clinical trials revealed no benefit for two drugs previously thought to be genetically validated, challenging previous assumptions about genetic research speed.
Limitations
Evidence is limited to the 2025 American Heart Association meeting; specific trial details, patient numbers, and long-term outcomes are not provided.
Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 14/11/2026, 11:01:19 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.
View archived briefing on IPFS
bafybeih3chkzsihs6brienjzbzqvikvubgfobbhwaonkowktghxj3pfxsq